SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

COLLABRX, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations - (Amounts in thousands)
[February 13, 2013]

COLLABRX, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations - (Amounts in thousands)

(Edgar Glimpses Via Acquire Media NewsEdge) Special Note Regarding Forward Looking Statements Information contained or incorporated by reference in this report contains forward-looking statements. These forward-looking statements are based on current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. These forward-looking statements should not be relied upon as predictions of future events as we cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. You can identify forward-looking statements by the use of forward-looking terminology such as "may," "will", "expect," "anticipate," "estimate" or "continue" or the negative thereof or other variations thereon or comparable terminology which constitutes projected financial information. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company including, but not limited to, industry conditions, economic conditions and acceptance of new technologies. For a discussion of the factors that could cause actual results to differ materially from the forward-looking statements, see "Part II, Item 1A.-Risk Factors" and the "Liquidity and Capital Resources" section set forth in this section and such other risks and uncertainties as set forth below in this report or detailed in our other SEC reports and filings. We assume no obligation to update forward-looking statements.

During fiscal years 2010 through 2012, we were engaged in the sale of product-line assets and intellectual property that we had either previously acquired or internally developed during the previous decade or more in the semiconductor and MEMS capital equipment industries. This effort followed extensive consideration by the Company's Board of Directors of our strategic options in light of the global financial crisis, rapidly declining sales and our relatively weak competitive position in those industries. Following the decision to sell assets or discontinue development programs associated with each of the major product lines, we classified those operations as "discontinued" and sought appropriate buyers. The first such sale of assets occurred on March 19, 2010, in which we sold our 6500 series and 900 series legacy etch products to OEM Group, Inc. At the end of Fiscal 2010, we discontinued our development efforts in our Nano Layer Deposition ("NLD") and Compact platform projects in an effort to reduce expenses and conserve capital. On February 9, 2011, we sold our Deep Reactive Ion Etch ("DRIE") product lines and technology, which we had acquired in 2008 from Alcatel Micro Machining Systems ("AMMS"), to SPP Process Technology Systems Limited ("SPTS"). This sale included all of the shares of Tegal France, SAS, the Company's wholly-owned subsidiary. On December 23, 2011, we sold a portfolio of 35 US and international patents in the areas of pulsed-chemical vapor deposition ("pulsed-CVD"), plasma-enhanced atomic layer deposition ("ALD"), and nano layer deposition ("NLD") to multiple IC and semiconductor equipment manufacturers, and we continue at the present time a marketing effort to sell additional related patents in our portfolio.

Throughout the fiscal years 2010 through 2012, we were continuously downsizing our operations, through transfers of our employees to other companies in connection with the sale of specific product lines, as well as through attrition and lay-offs. We also began a process of closing and/or liquidating all of our wholly-owned subsidiary companies, including SFI and Tegal GmbH, along with branches in Taiwan, Korea and Italy. As a result, all of our activities related to our legacy etch and PVD business, our DRIE business, our NLD development activities and our subsidiaries and branches are now included in discontinued operations.


Throughout most of fiscal 2012, our operations consisted mainly of our management agreement with Sequel Power, LLC, a company dedicated to development of large-scale solar photovoltaic ("PV") power plants and in providing related advisory services. In January of 2011, we contributed $2 million in cash to Sequel Power in exchange for an approximate 25% economic interest and voting control on its Board of Managers. In connection with the investment, our President and CEO was appointed Chairman of Sequel Power. In addition to our management role in Sequel Power, we were engaged in the sale of remaining intellectual property from our discontinued operations in semiconductor capital equipment and in researching potential new investment opportunities in several areas, including solar technology, medical devices and health technology.

On November 22, 2011, we made an investment of $300 in NanoVibronix, Inc. in the form of a convertible promissory note. NanoVibronix is a private company that develops medical devices and products that implement its proprietary therapeutic ultrasound technology which may be utilized for a variety of medical applications requiring low cost therapeutic ultrasound qualities. NanoVibronix is focused on creating products utilizing its unique, patented approach which enables the transmission of low-frequency, low-intensity ultrasound surface acoustic waves ("SAWs") through a variety of soft, flexible materials, including skin and tissue, enabling low-cost, breakthrough devices targeted at large, high-growth markets.

19-------------------------------------------------------------------------------- Index On June 29, 2012, we signed a definitive agreement to acquire CollabRx, Inc.

("CollabRx"), a privately held technology company in the rapidly growing market of interpretive content and data analytics for genomics-based medicine. The closing of our acquisition of CollabRx occurred on July 12, 2012. In connection with that transaction, we agreed to issue an aggregate of 236,433 shares of common stock, representing 14% of our total shares outstanding prior to the closing, to former CollabRx stockholders in exchange for 100% of the capital stock of CollabRx, Inc. The Company and certain former CollabRx stockholders entered into a Stockholders Agreement providing for, among other things, registration rights, transfer restrictions and voting and standstill agreements. We also assumed $500 of existing CollabRx indebtedness through the issuance of 5-year promissory notes in substitution for outstanding notes previously issued by CollabRx. In addition, we granted a total of 368,417 RSUs and options as "inducement grants" to newly hired management and employees, all subject to four-year vesting and other restrictions. At the closing, we appointed James M. Karis, former CEO of CollabRx to fill a vacancy on our Board of Directors and elected him Co-CEO. After the completion of the acquisition of CollabRx, the prior balance of a note receivable due from CollabRx was reclassified to be included as part of the purchase price.

CollabRx offers cloud-based expert systems that provide clinically relevant interpretive knowledge to institutions, physicians, researchers and patients for genomics-based medicine in cancer and other diseases to inform health care decision making. With access to approximately 50 clinical and scientific advisors at leading academic institutions and a suite of tools and processes that combine artificial intelligence-based analytics with proprietary interpretive content, the company is well positioned to participate in the $300 billion value-added "big data" opportunity in the US health care market (as reported by McKinsey Global Institute), over half of which specifically targets areas in cancer and cancer genomics. Originally founded in 2008, CollabRx has developed clinical advisory networks, expert systems, proprietary tools and processes, and a pipeline of commercial data products and applications ("apps") for cancer. CollabRx Therapy Finders™, its first commercial product, provides sophisticated, credible, personalized, and actionable information to physicians and patients for rapidly determining which medical tests, therapies, and clinical trials may be considered in cancer treatment planning with a specific emphasis on the tumor genetic profile.

CollabRx Therapy Finders™, the company's first commercial product, is a collection of web-based apps that serve as one type of user interface to access proprietary CollabRx content. Other interfaces include mobile apps, narrative published reports, statistical analyses and private-label, customized reports. CollabRx content is dynamically updated and organized in a knowledgebase that includes information on molecular diagnostics, medical tests, clinical trials, drugs, biologics and other information relevant for cancer treatment planning. Capturing how highly respected practicing physicians use this information in the clinical setting further refines the knowledgebase.

We intend that our most recent acquisition of CollabRx, Inc. will form the core of our operations going forward. Although we will continue to have an active role in the management of Sequel Power, we do not anticipate making any additional investments in that or any other solar-related businesses. In September 2012, the Company changed its name to "CollabRx, Inc." and the Company's common stock, which previously traded under the ticker symbol "TGAL" on the Nasdaq Capital Market, began trading under the new ticker symbol "CLRX".

We cannot assure you that we will be successful in pursuing our new strategic initiative in CollabRx. If our efforts do not succeed, we may need to raise additional capital which may include capital raises through the issuance of debt or equity securities. If additional funds are raised through the issuance of preferred stock or debt, these securities could have rights, privileges or preferences senior to those of our common stock, and debt covenants could impose restrictions on our operations. Moreover, such financing may not be available to us on acceptable terms, if at all. Failure to raise any needed funds would materially adversely affect us. It is not possible to predict when our business and results of operations will improve. In consideration of these circumstances, the Company may be forced to consider a merger with or into another company or the liquidation or dissolution of the Company, including through a bankruptcy proceeding. We cannot assure you that we will be successful in pursuing this or any other strategic alternatives. If we were to liquidate or dissolve the Company through or outside of a bankruptcy proceeding, you could lose all of your investment in the Company's common stock.

Critical Accounting Policies and Estimates We prepare the condensed consolidated financial statements in conformity with generally accepted accounting principles ("GAAP") in the United States which requires management to make certain estimates, judgments and assumptions that affect the reported amounts in the accompanying condensed consolidated financial statements, disclosure of contingent assets and liabilities and related footnotes. Accounting and disclosure decisions with respect to material transactions that are subject to significant management judgment or estimates include but are not limited to revenue recognition, accounting for stock-based compensation, accounts for receivables and allowance for doubtful accounts and impairment of long-lived assets. Actual results may differ from these estimates under different assumptions or conditions. Critical accounting policies are defined as those that are required for management to make estimates, judgments and assumptions giving due consideration to materiality, in certain circumstances that affect amounts reported in the condensed, consolidated financial statements, and potentially result in materially different results under different conditions and assumptions. We based these estimates and assumptions on historical experience and evaluate them on an on-going basis to help ensure they remain reasonable under current conditions. Actual results could differ from those estimates. During the three and nine months ended December 31, 2012, there were no significant changes to the critical accounting policies and estimates discussed in the Company's 2012 Annual Report on Form 10-K.

20-------------------------------------------------------------------------------- Index Pension Obligations Prior to fiscal year 2011, the Company began the process of closing and/or liquidating all of our wholly-owned subsidiary companies, not already sold, including our German subsidiary. The subsidiaries are now included in discontinued operations. The Company has recognized an ongoing liability for pensions related to the German subsidiary. However, in fiscal year 2011, the Company recognized an additional liability for the independent third-party administration of the pension program. The total pension liability in the prior period was $700. The pension liability was settled on October 6, 2011, and the total pension liability as of December 31, 2012 was $0. The settlement of the pension obligation was classified as a reduction of liabilities of discontinued operations. The related foreign exchange gain of $23 was classified as a gain or loss on the sale of discontinued operations in the third quarter of the prior fiscal year. The Company has no future pension obligations.

Results of Operations The following table sets forth certain financial items for the three and nine months ended December 31, 2012 and 2011: Three Months Ended Nine Months Ended December 31, December 31, 2012 2011 2012 2011 Revenue $ - $ - $ 50 $ - Revenue - related party 25 38 75 75 Total revenue 25 38 125 75 Cost of revenue 18 -- 38 -- Gross profit 7 38 87 75 Operating expenses: Engineering -- -- 328 -- Research and development 285 -- 285 -- Sales and marketing expenses 127 -- 176 -- General and administrative expenses 864 432 2,546 1,873 Total operating expenses 1,276 432 3,335 1,873 Operating loss (1,269 ) (394 ) (3,248 ) (1,798 ) Equity in loss of unconsolidated affiliate -- (181 ) -- (501 ) Other income (expense), net 9 (8 ) 29 6 Loss before income tax benefit (1,260 ) (583 ) (3,219 ) (2,293 ) Income tax benefit (52 ) -- (52 ) -- Loss from continuing operations (1,208 ) (583 ) (3,167 ) (2,293 ) Income from discontinued operations, net of taxes 56 2,852 52 3,091 Net (loss) income and comprehensive (loss) income $ (1,152 ) $ 2,269 $ (3,115 ) $ 798 Net loss per share from continuing operations: Basic and diluted $ (0.64 ) $ (0.34 ) $ (1.76 ) $ (1.36 ) Net income per share from discontinued operations: Basic and diluted $ 0.03 $ 1.69 $ 0.03 $ 1.83 Net (loss) income per share: Basic and diluted $ (0.61 ) $ 1.35 $ (1.73 ) $ 0.47 Weighted-average shares used in per share computation: Basic and diluted 1,884 1,689 1,798 1,689 21-------------------------------------------------------------------------------- Index Revenue Immediately prior to the acquisition of CollabRx, the Company's sole source of revenue was from management activities related to Sequel Power. Sequel Power is a related party. Revenue for the three months ended December 31, 2012 decreased by $13 compared to the three months ended December 31, 2011, and revenue for the nine months ended December 31, 2012 increased by $50 from revenue for the nine months ended December 31, 2011. The decrease in the three month period relates to a change in Sequel Power revenue during the prior period. The increase in the nine month period is related to our acquisition of CollabRx.

As a percentage of total revenue for the three and nine months ended December 31, 2012 and 2011, international sales were 0%. The Company's historical operations had revenues in international markets. With the acquisition of CollabRx and if the continued solar project activities of Sequel Power are successful, we expect that international sales will once again account for a significant portion of any future revenue.

All DRIE related revenues and expenses are captured in Discontinued Operations in our statement of operations and comprehensive loss.

Gross Profit Gross profit for the three and nine months ended December 31, 2012 decreased $31 and increased by $12, respectively, from our gross profit of $38 and $75 for the three and nine months ended December 31, 2011. Our gross profit for the three and nine months ended December 31, 2012 reflects the amortization of the Company's product specific software, which was included in the CollabRx acquisition.

Our gross margin for the three and nine months ended December 31, 2012 were 28.0% and 69.6%, respectively. Our gross margin for the three and nine months ended December 31, 2011, respectively, was 100%, as all revenues were management services revenues and no costs were incurred to record this revenue.

At the present time our core operations consist primarily in the commercial application of the CollabRx technology and content. We offer cloud-based expert systems that provide clinically relevant interpretive knowledge to institutions, physicians, researchers and patients for genomics-based medicine in cancer and other diseases to inform health care decision-making. While we and our advisors do not provide specific treatment recommendations, this clinically relevant knowledge is a key part of the "context engine" for informing healthcare decision-making.

We expect that we will continue to be involved in supporting the activities of Sequel Power through our direct management efforts.

Engineering Following the acquisition of CollabRx, engineering expenses consist primarily of salaries. Prior to the sale of the DRIE related assets, engineering expenses consisted primarily of salaries, prototype material and other costs associated with our ongoing systems and process technology development, applications and field process support efforts. The difference in Engineering expense of $328 for the nine months ended December 31, 2012, compared to the same period in 2011, resulted from the CollabRx acquisition and the employees retained for those operations. The difference in Engineering expense compared to the second quarter of the current fiscal year resulted from the year-to-date change in categorization of certain employee related expenses from engineering to research and development. (See "Research and Development" below.) The Company had no expenses associated with engineering for the three and nine months ended December 31, 2011 due to the exit from our core historical DRIE operations.

Research and Development The expenses in research and development ("R&D") resulted from the change in categorization of certain employee related expenses from engineering to R&D. The efforts of the engineering group include supporting existing product offerings as well as developing future product offerings. Consequently, these expenses have been segregated, and these expenses make up the total R&D expenses for the three and nine months ended December 31, 2012. The Company had no expenses associated with R&D for continuing operations for the three and nine months ended December 31, 2011 due to the exit from our core historical DRIE operations.

22-------------------------------------------------------------------------------- Index As a result of the sale of the Company's DRIE related assets, and in accordance with generally accepted accounting principles, the DRIE business operation, including related and ongoing R&D expenses, have all been reclassified to discontinued operations. For the nine months ended December 31, 2011, the Company's R&D expenses were related to the NLD product line, the assets of which were held for sale and sold to third parties. R&D expenses for that period were also related to analyzing and evaluating various opportunities that the Company was reviewing as possible merger or acquisition opportunities in other diversified technologies.

Sales and Marketing Following the acquisition of CollabRx, sales and marketing expenses consist primarily of salaries. Prior to the sale of the DRIE related assets, sales and marketing expenses consisted primarily of salaries, commissions, trade show promotion and travel and living expenses associated with those functions. The change in sales and marketing expense of $127 and $176 for the three and nine months ended December 31, 2012, compared to the same periods in 2011, resulted from the CollabRx acquisition. The Company had no expenses associated with sales and marketing for the three and nine months ended December 31, 2011 due to the exit from our core historical DRIE operations.

General and Administrative General and administrative expenses consist of salaries, legal, accounting and related administrative services and expenses associated with general management, finance, information systems, human resources and investor relations activities. The increase of continuing general and administrative expenses of $432 and $673 for the three and nine month periods ended December 31, 2012 compared to the same periods in 2011 was due primarily to stock related compensation associated with the issuance of inducement grants and employee bonuses for key employees. Expenses for legal and consulting services also increased in connection with the acquisition of CollabRx.

Equity in Loss of Unconsolidated Affiliate The Company recorded a loss in earnings of the unconsolidated affiliate of $0 and no amortization expenses related to the difference between the net book value of Sequel Power's assets and the cost of the investment for the three and nine months ended December 31, 2012. The Company recorded a loss in earnings of the unconsolidated affiliate of $138 and $43 of amortization expenses related to the difference between the net book value of Sequel Power's assets and the cost of the investment for the three months ended December 31, 2011. The Company recorded a loss in earnings of the unconsolidated affiliate of $372 and $129 of amortization expenses related to the difference between the net book value of Sequel Power's assets and the cost of the investment for the nine months ended December 31, 2011. Currently, the net book value of the Sequel Power investment is zero.

Other Income (Expense), net Other income (expense), net consists of the change in fair value of the common stock warrant liability and interest earned on our NanoVibronix investment.

Income Taxes As a result of the stock purchase of CollabRx during the nine months ended December 31, 2012, the Company had no tax basis in the intangible assets acquired. During the three months ended December 31, 2012, the Company recognized $52 in tax benefit as a result of this difference.

During the three and nine months ended December 31, 2011, there was no income tax expense or benefit for federal and state income taxes reflected in our condensed consolidated statements of operations due to our net loss and a valuation allowance on the resulting deferred tax asset.

As of March 31, 2012, the Company had net operating loss carryforwards of approximately $98.7 million and $47.5 million for federal and state tax purposes, respectively. The federal net operating loss carryforward will begin to expire in the year ended March 31, 2020 and the state of California net operating loss carryforward will start to expire in the year ended March 31, 2013. At March 31, 2012, the Company also had research and experimentation credit carryforwards of $1.3 million and $0.8 million for federal and state income tax purposes, respectively. A portion of the federal credit began to expire in the year ended March 31, 2012 and the state of California will never expire under current law. Net operating loss carryforwards and R&D credits can only offset 90% of taxable income.

23-------------------------------------------------------------------------------- Index Discontinued Operations Discontinued operations consists of interest income from accounts related to discontinued operations, other income, gains and losses on the disposal of fixed assets of discontinued operations, gains and losses on foreign exchange and interest income on money market accounts, as well as the reclassification of net expenses associated with our exit from our historical core operations. For the three and nine months ended December 31, 2012 compared to the nine months ended December 31, 2011, net gain from discontinued operations decreased by $2,796 and $3,039, respectively. The decreases resulted from the Company's recognition of $3,550 from the December 23, 2011 sale of the NLD patents in December 2011. As these assets were internally developed, there was a corresponding zero book value. The NLD revenue was recognized in discontinued operations, along with the related costs of $813, which includes $767 in commission expense.

In the nine months ended December 31, 2012, discontinued operations included discontinued R&D expenses. These expenses were offset by the net settlement of legal expenses related to closing a foreign subsidiary. The full amount of the legal expense was accrued in the prior fiscal year.

Prior to the sale of the DRIE related assets, R&D expenses consisted primarily of salaries, prototype material and other costs associated with our ongoing systems and process technology development, applications and field process support efforts for our DRIE product line. As a result of the sale of the Company's historical DRIE related assets, and in accordance with generally accepted accounting principles, the DRIE business operation, including related and continuing R&D expenses, have all been reclassified to discontinued operations. At the time of the DRIE sale, all the Company's R&D expenses were related to the DRIE operations. Currently the Company records legacy related R&D expenses in discontinued operations. Such expenses are immaterial. These R&D expenses are related to the NLD product line, the assets of which are held for sale to third parties.

Contractual Obligations The following summarizes our contractual obligations as of December 31, 2012, and the effect such obligations are expected to have on our liquidity and cash flows in future periods (in thousands).

Contractual obligations: Less than After Total 1 Year 1-3 Years 3-5 Years 5 Years Non-cancelable operating lease obligations $ 581 $ 109 $ 247 $ 225 $ Total contractual cash obligations $ 581 $ 109 $ 247 $ 225 $ - Most leases provide for the Company to pay real estate taxes and other maintenance expenses. Rent expense for operating leases related to discontinued operations, net of sublease income, was $0 for the nine months ended December 31, 2012. Rent expense for operating leases related to continuing operations, net of sublease income, was $15 for each of the three month periods ended December 31, 2012 and 2011, respectively. Rent expense for operating leases related to continuing operations, net of sublease income, was $55 and $72 for the nine month periods ended December 31, 2012 and 2011, respectively.

As of September 1, 2012, we maintain our headquarters, encompassing our executive office and storage areas in San Francisco, California. We have a primary lease for office space, consisting of 2,614 square feet, which expires August 31, 2017. Prior to moving to San Francisco, we were located in Petaluma, California. We had a primary lease for office space, consisting of 2,187 square feet, which expired August 31, 2012. We rent storage/workspace areas on a monthly basis. We own all of the equipment used in our facilities. Such equipment consists primarily of computer related assets.

Certain of our past sales contracts included provisions under which customers would be indemnified by us in the event of, among other things, a third party claim against the customer for intellectual property rights infringement related to our products. There were no limitations on the maximum potential future payments under these guarantees. We have accrued no amounts in relation to these provisions as no such claims have been made, and we believe we have valid, enforceable rights to the intellectual property embedded in its products.

Liquidity and Capital Resources For the nine months ended December 31, 2012, and the fiscal year ended March 31, 2012, we financed our operations from existing cash on hand. Net cash used in operating activities during the nine months ended December 31, 2012, was $2,833. The primary changes in our cash flow statement for the nine months ended December 31, 2012 compared to the corresponding period in the prior fiscal year were due to our acquisition of CollabRx, a net loss of $3,115, and stock compensation expense, partially offset by a VAT refund related to the discontinued operations in our former French subsidiary in the amount of 312 euros. Net cash used in operating activities during the nine months ended December 31, 2011 was $2,273, due primarily to the income of $3,550 recognized from the December 23, 2011 sale of the NLD patents. As these assets were internally developed, there was a corresponding zero book value. The monies from the patent sale were offset by the net loss from continuing operations of $2,293, and decreases in the net value of current assets and liabilities of discontinued operations and other assets related to our Sequel Power investment, offset by the decrease in accounts payable.

24-------------------------------------------------------------------------------- Index The consolidated financial statements contemplate the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future. We incurred a net loss of $3,115 and a net gain of $798 for the nine months ended December 31, 2012 and 2011, respectively. We used cash flows from operations of $2,833 and $2,273 for the nine months ended December 31, 2012 and 2011, respectively. We believe that our existing cash balances will be adequate to fund operations through fiscal year 2014. CollabRx, Inc. will form the core of our business and operations going forward. Although we will continue to have an active role in the management of Sequel Power, we do not anticipate making any additional investments in that or any other solar-related businesses. We cannot assure you that we will be successful in pursuing our new strategic initiative in CollabRx. It is not possible to predict when our business and results of operations will improve. In consideration of these circumstances, the Company may be forced to consider a merger with or into another company or the liquidation or dissolution of the company, including through a bankruptcy proceeding. If we were to liquidate or dissolve the company through or outside of a bankruptcy proceeding, you could lose all of your investment in the Company's common stock.

Off-Balance Sheet Arrangements We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.

[ Back To TMCnet.com's Homepage ]





LATEST VIDEOS

DOWNLOAD CENTER

UPCOMING WEBINARS

MOST POPULAR STORIES





Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.